Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases
Primary Purpose
Hepatocellular Cancer, Cholangiocarcinoma, Hepatic Metastases
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Proton Beam Radiation
Sponsored by
About this trial
This is an interventional treatment trial for Hepatocellular Cancer focused on measuring proton beam irradiation, liver cancer
Eligibility Criteria
Inclusion Criteria:
- Biopsy proven unresectable or locally recurrent hepatocellular cancer, cholangiocarcinoma, or hepatic metastases.
- Primary lesion size of 6cm or less in greatest diameter
- Single or multinodular tumors (up to 3)
- 18 years of age or older
- No evidence of extrahepatic tumor
- Karnofsky performance status of 70-100
- If patient has underlying cirrhosis, only Child's classification Group A or Group B
- Adequate renal function
- Expected survival of greater than three months
Exclusion Criteria:
- Pregnant or lactating women
- Evidence of non-hepatic metastatic disease
- Local conditions or systemic illnesses which would reduce the local tolerance to radiation treatment, such as serious local injuries, active collagen vascular disease, etc.
- Prior radiation treatment to affected region
- Serious psychiatric illness which would limit compliance with treatment
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Proton Beam Radiation
Arm Description
Proton radiation therapy
Outcomes
Primary Outcome Measures
To determine the maximum tolerated dose (MTD) of proton beam irradiation in patients with unresectable or locally recurrent hepatocellular cancer, cholangiocarcinoma, or hepatic metastases.
Secondary Outcome Measures
To determine safety and tolerance of this treatment program
to evaluate tumor response, local control and survival in this patient population.
Full Information
NCT ID
NCT00465023
First Posted
April 23, 2007
Last Updated
January 19, 2017
Sponsor
Massachusetts General Hospital
Collaborators
National Cancer Institute (NCI), Dana-Farber Cancer Institute, Brigham and Women's Hospital
1. Study Identification
Unique Protocol Identification Number
NCT00465023
Brief Title
Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases
Official Title
Phase I Study of Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases
Study Type
Interventional
2. Study Status
Record Verification Date
January 2017
Overall Recruitment Status
Completed
Study Start Date
June 2003 (undefined)
Primary Completion Date
September 2013 (Actual)
Study Completion Date
January 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Massachusetts General Hospital
Collaborators
National Cancer Institute (NCI), Dana-Farber Cancer Institute, Brigham and Women's Hospital
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The main purpose of this study is to determine if high doses of radiation using proton beam can be given safely with low and acceptable side effects. We will also gather information to determine the ability of proton beam to destroy cancer cells in the liver. There are two types of external radiation treatments (proton beam and photon beam). Proton beam radiation is a very accurate kind of treatment that has been shown to affect less normal tissue than a regular radiation beam. The accuracy allows us to more safely increase the amount of radiation delivered to eliminate cancer and may potentially reduce the side effects normally experienced with standard radiation therapy.
Detailed Description
Participants will receive treatment as an outpatient at the Northeast Proton Treatment Center located at the Massachusetts General Hospital.
Since we are looking for the highest dose of proton beam radiation that can be given to people safely, not everyone who participates in this study will be receiving the same amount of radiation. Small groups of people will be enrolled and given a certain dose of radiation. If they tolerate it well, the next small group of people enrolled will receive a higher dose. This will continue until we find the highest dose that can be given without causing serious or unmanageable side effects.
Radiation treatment to the liver will be given once a day, 5 days a week (Monday-Friday), for 3 weeks. Each treatment takes about 10-20 minutes.
A physical examination, medical history, and blood tests will be taken once a week for 3 weeks during radiation therapy. Follow-up visits will occur every 3 months for 2 years, and every 6 months thereafter for 3 years, and then annually thereafter.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatocellular Cancer, Cholangiocarcinoma, Hepatic Metastases
Keywords
proton beam irradiation, liver cancer
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
16 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Proton Beam Radiation
Arm Type
Experimental
Arm Description
Proton radiation therapy
Intervention Type
Procedure
Intervention Name(s)
Proton Beam Radiation
Intervention Description
Once a day, 5 days a week (Monday-Friday) for 3 weeks.
Primary Outcome Measure Information:
Title
To determine the maximum tolerated dose (MTD) of proton beam irradiation in patients with unresectable or locally recurrent hepatocellular cancer, cholangiocarcinoma, or hepatic metastases.
Time Frame
4 years
Secondary Outcome Measure Information:
Title
To determine safety and tolerance of this treatment program
Time Frame
4 years
Title
to evaluate tumor response, local control and survival in this patient population.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Biopsy proven unresectable or locally recurrent hepatocellular cancer, cholangiocarcinoma, or hepatic metastases.
Primary lesion size of 6cm or less in greatest diameter
Single or multinodular tumors (up to 3)
18 years of age or older
No evidence of extrahepatic tumor
Karnofsky performance status of 70-100
If patient has underlying cirrhosis, only Child's classification Group A or Group B
Adequate renal function
Expected survival of greater than three months
Exclusion Criteria:
Pregnant or lactating women
Evidence of non-hepatic metastatic disease
Local conditions or systemic illnesses which would reduce the local tolerance to radiation treatment, such as serious local injuries, active collagen vascular disease, etc.
Prior radiation treatment to affected region
Serious psychiatric illness which would limit compliance with treatment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Theodore S. Hong, MD
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases
We'll reach out to this number within 24 hrs